Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Saved in:
Bibliographic Details
Title: Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Authors: Cohen, E. E. W.1 ecohen@ucsd.edu, Licitra, L. F.2,3, Burtness, B.4, Fayette, J.5,6, Gauler, T.7, Clement, P. M.8, Grau, J. J.9, del Campo, J. M.10, Mailliez, A.11, Haddad, R. I.12,13, Vermorken, J. B.14, Tahara, M.15, Guigay, J.16, Geoffrois, L.17, Merlano, M. C.18, Dupuis, N.19, Krämer, N.20, Cong, X. J.21, Gibson, N.22, Solca, F.23
Source: Annals of Oncology. Oct2017, Vol. 28 Issue 10, p2526-2532. 7p. 3 Charts.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdx344